FDA approves subcutaneous injectable for myasthenia gravis treatment.

The FDA has approved a new injectable version of argenx's autoimmune disease drug Vyvgart, marketed as Vyv­gart Hytru­lo, for people with generalized myasthenia gravis. The condition causes a person's immune system to make antibodies that attack their muscles, making movement, speaking, and swallowing difficult and life-threatening when it impedes breathing. The new version will be available in July.